Pacific Biosciences of California (PACB) - Total Liabilities

Latest as of June 2026: $785.06 Million USD

Based on the latest financial reports, Pacific Biosciences of California (PACB) has total liabilities worth $785.06 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Pacific Biosciences of California to evaluate the company's liquid asset resilience ratio.

Pacific Biosciences of California - Total Liabilities Trend (2008–2025)

This chart illustrates how Pacific Biosciences of California's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Pacific Biosciences of California total assets.

Pacific Biosciences of California Competitors by Total Liabilities

The table below lists competitors of Pacific Biosciences of California ranked by their total liabilities.

Company Country Total Liabilities
Polyplex (Thailand) Public Company Limited
BK:PTL
Thailand ฿6.23 Billion
Clearpoint Neuro Inc
NASDAQ:CLPT
USA $75.97 Million
GuangDong GenSho Logistics Co
SHG:603813
China CN¥1.03 Billion
Aydem Yenilenebilir Enerji AS
IS:AYDEM
Turkey TL33.69 Billion
Power Wind Health Industry Incorporated
TW:8462
Taiwan NT$9.35 Billion
Shandong Hiking International Co Ltd Class A
SHG:600735
China CN¥427.87 Million
Shanghai Kai Kai Industry Co Ltd A
SHG:600272
China CN¥940.14 Million
Marshall Boya ve Vernik Sanayi AS
IS:MRSHL
Turkey TL3.06 Billion

Liability Composition Analysis (2008–2025)

This chart breaks down Pacific Biosciences of California's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See how leveraged is Pacific Biosciences of California's balance sheet to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 4.92 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity -23.64 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 1.04 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Pacific Biosciences of California's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Pacific Biosciences of California (2008–2025)

The table below shows the annual total liabilities of Pacific Biosciences of California from 2008 to 2025.

Year Total Liabilities Change
2025-12-31 $778.73 Million +3.30%
2024-12-31 $753.85 Million -27.84%
2023-12-31 $1.04 Billion -13.24%
2022-12-31 $1.20 Billion -0.97%
2021-12-31 $1.22 Billion +1449.24%
2020-12-31 $78.49 Million -15.66%
2019-12-31 $93.07 Million +65.56%
2018-12-31 $56.21 Million -3.05%
2017-12-31 $57.98 Million +8.95%
2016-12-31 $53.22 Million -7.56%
2015-12-31 $57.57 Million -17.26%
2014-12-31 $69.57 Million +3.83%
2013-12-31 $67.00 Million +230.06%
2012-12-31 $20.30 Million -24.40%
2011-12-31 $26.85 Million +3.76%
2010-12-31 $25.88 Million -90.70%
2009-12-31 $278.22 Million +34.73%
2008-12-31 $206.50 Million --

About Pacific Biosciences of California

NASDAQ:PACB USA Medical Devices
Market Cap
$416.51 Million
Market Cap Rank
#13443 Global
#3260 in USA
Share Price
$1.34
Change (1 day)
-0.74%
52-Week Range
$1.11 - $2.67
All Time High
$51.15
About

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stran… Read more